Unlocking the Future of Oncology at World GU 2025

At the forefront of groundbreaking discussions, hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, took center stage at the 2025 World Conference on Genitourinary Cancers (World GU). Their mission? To delve into the latest innovations in genitourinary oncology and how they can transform patient care.

Tailored Treatments for Prostate Cancer Patients

Highlighting the complexities of prostate cancer, the experts zeroed in on treatment strategies for unique patient subgroups, particularly those with small cell histology or neuroendocrine features. They discussed how a combination of androgen deprivation therapy, chemotherapy, and radiation could enhance patient outcomes, especially in community oncology settings.

Navigating Bladder Cancer Variants: A New Approach

The conversation then shifted to the challenges posed by bladder cancer variants such as papillary and plasmacytoid forms. Through a careful analysis of existing data and clinical experiences, they outlined optimal treatment regimens like the combination of enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda), tailored to the patient’s specific presentation.

Innovative Strategies for Kidney Cancer Management

Next on the agenda was the assessment of kidney cancer variants, including clear cell and chromophobe types. The panel of experts debated when to implement VEGF inhibitors and tyrosine kinase inhibitors, emphasizing the paramount importance of histological observation in treatment decisions.

Meet the Experts Driving Change

Bupathi and Garmezy are not just discussing theory; they are leaders in the field. Bupathi serves as the executive co-chair of the Genitourinary Cancer Research Executive Committee at the Sarah Cannon Research Institute and is a noted medical oncologist specializing in solid tumors. Garmezy, also an executive co-chair at SCRI, is dedicated to advancing research in genitourinary cancers.

Joining them was Bradley G. Somer, MD, a senior partner at the Executive Cancer Council and president of the West Cancer Center & Research Institute, sharing insights that could redefine clinical practices.

The Future is Bright for Genitourinary Oncology

With such expertise converging, the dialogue at World GU 2025 promises to shape the future of genitourinary cancer management. Stay tuned as these pioneers continue to innovate and inspire change in oncology!